Presentation is loading. Please wait.

Presentation is loading. Please wait.

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities  Matthew P. Humphries, PhD, Stephen.

Published byKristopher Alexander Modified over 5 years ago

Similar presentations

Presentation on theme: "Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities  Matthew P. Humphries, PhD, Stephen."— Presentation transcript:

1 Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities  Matthew P. Humphries, PhD, Stephen McQuaid, PhD, Stephanie G. Craig, PhD, Victoria Bingham, MSc, Perry Maxwell, PhD, Manisha Maurya, PhD, Fiona McLean, BSc, James Sampson, MBChB, Patricia Higgins, BSc, Christine Greene, BSc, Jacqueline James, PhD, Manuel Salto-Tellez, MBChB  Journal of Thoracic Oncology  Volume 14, Issue 1, Pages (January 2019) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Summary of the validation on tissue microarrays of the programmed death ligand 1 (PD-L1) SP263 clone on Ventana BenchMark against the Dako PD-L1 22C3 clone on the Dako Autostainer Link 48 in (A) lung adenocarcinomas and (B) squamous cell carcinomas. A very high level of concordance was observed. For adenocarcinomas, there were 111 of 113 tissue microarray (TMA) cores (98%); and for squamous cell carcinomas, there were 100 of 103 TMA cores (97%). (C) For (i) 22C3 and (ii) SP263 there is no PD-L1 expression in lung adenocarcinoma, whereas (iii) 22C3 and (iv) SP263 show comparable expression of more than 50% on tumor epithelium in a squamous cell carcinoma. And in (v) 22C3, two or three tumor epithelial cells are expressing PD-L1, but this expression was not observed in a serial core with the SP263 clone (vi). Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Comparable categorical distribution of programmed death ligand 1 (PD-L1) expression. (A) Within all 564 clinical cases. (B) In adenocarcinomas. (C) In squamous cell carcinomas. Inadequate cases were defined as those which had insufficient tumor content (<100 malignant cells) available for analysis. (D, E) Left-to-right display representative images of (i) hematoxylin and eosin staining (H&E), (ii) negative PD-L1 expression, (iii) 1% to 49% PD-L1 expression, and (iv) more than 50% positive PD-L1 expression for adenocarcinoma and squamous cells carcinoma, respectively. Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Range of sample types tested, including tumor content available for programmed death ligand 1 (PD-L1) testing. (A) The range of samples types received for testing, resection, biopsy and cell block (CB). (B) Confirms that tumor content availability did not significantly affect the PD-L1 category determined. (C) PD-L1 expression according to sample type. p value is determined by the chi-square test. (D) PD-L1 expression within the cases of differing EGFR status. Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Challenges with programmed death ligand 1 (PD-L1) assessments. (A) PD-L1 expressing tumor cells in a cell block which are confirmed by TTF1 expression a highly specific marker for primary lung adenocarcinomas. The case was reported as more than 50% PD-L1 expression in tumor cells. (B) PD-L1 expression in foci of cells in a lung cell block which, when phenotyped with macrophage and epithelial markers, were identified as macrophages. The case was reported as PD-L1–negative. (C) Resection of adenocarcinoma in which there is strong expression of PD-L1 on lymphocytes which “hug” the tumor. (D) Resection sample from squamous cell carcinoma shows distinct heterogeneity of PD-L1 expression ranging from absent to more than 50% expression in various fields across the tumor bed. TTF-1, thyroid transcription factor 1; HE, hematoxylin and eosin. Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplemental Figure 1 Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplemental Figure 2 Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

8 Supplemental Figure 3 Journal of Thoracic Oncology  , 45-53DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities  Matthew P. Humphries, PhD, Stephen."

Similar presentations

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies  Arantza Azpilikueta,

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies  Arantza Azpilikueta,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Nicole R. Murray, Verline Justilien, Alan P. Fields  Cancer Cell 

Nicole R. Murray, Verline Justilien, Alan P. Fields  Cancer Cell 
Kenneth Daily, Amy Coxon, Jonathan S. Williams, Chyi-Chia R

Kenneth Daily, Amy Coxon, Jonathan S. Williams, Chyi-Chia R
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,
ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit,

ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.
Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Intrathoracic Lymphadenopathy in Patients with Extrathoracic Malignancy:

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Intrathoracic Lymphadenopathy in Patients with Extrathoracic Malignancy:
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches  Matthew.

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches  Matthew.

Similar presentations

Ads by Google